Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Schweizer

Showing results (201-210 of 267) with videos related to

Pageof 27
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received <sup>177</sup>Lu-PSMA-617: Importance of <sup>18</sup>F-FDG-Avid Discordant FindingsRidvan Arda Demirci, Alireza Ghodsi, Roman Gulati, et al.
Stem Cells Translational Medicine|March 30, 2019
In ReplyW Nathaniel Brennen, Michael T Schweizer, Hao Wang, et al.
Stem Cells Translational Medicine|February 9, 2019
A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate CancerMichael T Schweizer, Hao Wang, Trinity J Bivalacqua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate CancerElahe A Mostaghel, Brett T Marck, Orpheus Kolokythas, et al.
The Journal of Clinical Investigation|July 17, 2019
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damagePayel Chatterjee, Michael T Schweizer, Jared M Lucas, et al.
Clinical Genitourinary Cancer|June 21, 2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy StudyFady Ghali, Funda Vakar-Lopez, Martine P Roudier, et al.
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
European Urology|June 23, 2019
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsHung-Ming Lam, Holly M Nguyen, Mark P Labrecque, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
Pageof 27

Showing results (201-210 of 267) with videos related to

Sort By:
Pageof 27
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received <sup>177</sup>Lu-PSMA-617: Importance of <sup>18</sup>F-FDG-Avid Discordant FindingsRidvan Arda Demirci, Alireza Ghodsi, Roman Gulati, et al.
Stem Cells Translational Medicine|March 30, 2019
In ReplyW Nathaniel Brennen, Michael T Schweizer, Hao Wang, et al.
Stem Cells Translational Medicine|February 9, 2019
A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate CancerMichael T Schweizer, Hao Wang, Trinity J Bivalacqua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate CancerElahe A Mostaghel, Brett T Marck, Orpheus Kolokythas, et al.
The Journal of Clinical Investigation|July 17, 2019
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damagePayel Chatterjee, Michael T Schweizer, Jared M Lucas, et al.
Clinical Genitourinary Cancer|June 21, 2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy StudyFady Ghali, Funda Vakar-Lopez, Martine P Roudier, et al.
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
European Urology|June 23, 2019
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsHung-Ming Lam, Holly M Nguyen, Mark P Labrecque, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
Pageof 27